Real-World Analysis of Initial Clinical Response and Future Outcomes Among Patients with Rheumatoid Arthritis Initiating and Remaining on a First-Line Tumor Necrosis Factor Inhibitor in the United States

By afschroeder • November 15, 2025

Charles-Schoeman C, Zueger P, McDearmon-Blondell E, Fang S, Peng Y, Oishi T, Jain M, Tesser J. Real-World Analysis of Initial Clinical Response and Future Outcomes Among Patients with Rheumatoid Arthritis Initiating and Remaining on a First-Line Tumor Necrosis Factor Inhibitor in the United States. Rheumatol Ther. 2025 Nov 14. doi: 10.1007/s40744-025-00808-z. Epub ahead of print. PMID: 41239038.

Tags: Biologic disease-modifying antirheumatic drug(bDMARD), Clinical Disease Activity Index(CDAI), Publications, Rheumatoid arthritis(RA), Rheumatology, Tumor necrosis factor inhibitor(TNFi)

Glaucomatous Remodeling of the Lamina Cribrosa: Association With Visual Field Progression

Girkin CA, Walker E, Gardiner SK, Hallaj S, Murillo K, Jiravarnsirikul A, Weinreb RN, Liebmann JM, Zangwill LM, Fazio MA. Glaucomatous Remodeling of the Lamina[...]

Blood Pressure Genetic Risk and Incident Hypertension at 2 to 7 Years Post Partum

Hemeryck J, De Moor N, Ezzat D, Khan RR, Vandergrift N, Levine LD, Rouse C, Theilen LH, Bairey Merz CN, Yee LM, Chung J, Bello[...]

Time to Quadruple Therapy After Initial Diagnosis of Heart Failure With Reduced Ejection Fraction

Jacobs JA, Greene T, Vanneman ME, Kean J, Carter SJ, Shah KS, Pandey A, Derington CG, Zheutlin AR, Fang J, Stehlik J, Fonarow GC, Bress[...]